From 1 September 2023, the Medicare Benefits Schedule (MBS) item for Programmed Cell Death Ligand immunohistochemistry testing (72814) will be amended to include testing for patients with locally recurrent unresectable or metastatic advanced triple negative breast cancer.
Further information can be found in the Factsheet below:
PDF Version Factsheet Amendment to item 72814 for PD-L1 testing to include testing for advanced triple negative breast cancer patients (PDF 180 KB)
Word Version Factsheet Amendment to item 72814 for PD-L1 testing to include testing for advanced triple negative breast cancer patients (Word 131 KB)